Skip to main content

Table 2 Multivariable models of variables associated with endocrine initiation among women tested by Oncotype Dx (N = 1528) and women who were eligible for testing by Oncotype Dx (N = 4674)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

  Oncotype Dx-tested Oncotype Dx-eligible
  OR (95% CI) P OR (95% CI) P
Recurrence score    0.02    
 Low (ref)       
 Intermediate 0.98 (0.64–1.50)     
 High 0.40 (0.20–0.81)     
Tested       <0.001
 Yes     2.48 (2.03–3.04)  
 No (ref)       
Year diagnosed    0.13    0.004
 2006–2007 (ref)       
 2008–2009 0.74 (0.49–1.13)   0.74 (0.61–0.89)  
 2010–2012 1.17 0.65–2.09)   0.89 (0.70–1.15)  
Age at diagnosis    0.20    <0.001
 24–39 0.49 (0.24–1.01)   0.59 (0.43–0.82)  
 40–49 0.73 (0.48–1.11)   0.74 (0.60–0.90)  
 50–59 (ref)       
 60–63 0.80 (0.49–1.30)   1.01 (0.80–1.27)  
Race-ethnicity    0.06    0.19
 NH white (ref)       
 NH black 3.62 (0.83–15.81)   0.92 (0.61–1.38)  
 Hispanic 0.62 (0.27–1.41)   0.89 (0.60–1.33)  
 Other 2.52 (0.89–7.13)   1.44 (1.01–2.06)  
Marital status    0.16    0.12
Married (ref)       
Not married 0.76 (0.52–1.11)   0.87 (0.72–1.04)  
Prior cancer    0.65    0.84
 No (ref)       
 Yes 1.21 (0.52–2.80)   1.04 (0.71–1.53)  
State       0.004
 CA (ref)       
 GA 0.62 (0.32–1.20)   1.15 (0.85–1.55)  
 KY 1.73 (0.72–4.14)   1.71 (1.19–2.47)  
 NY 1.05 (0.50–2.19)   1.60 (1.16–2.20)  
 OH 1.20 (0.58–2.50)   1.45 (1.05–2.00)  
Area    0.74    0.70
 Rural (ref)       
 Urban 1.17 (0.47–2.92)   1.08 (0.74–1.56)  
Median household income    0.24    0.07
 1 (lowest (ref))       
 2 1.23 (0.68–2.22)   0.96 (0.74–1.26)  
 3 1.00 (0.57–1.76)   0.97 (0.74–1.26)  
 4 1.84 (0.97–3.49)   1.35 (1.02–1.82)  
 5 (highest) 1.10 0.59–2.07)   1.01 (0.75–1.36)  
Stage    0.14    0.52
 I (ref)       
 II 0.71 (0.45–1.12)   0.92 (0.71–1.19)  
Nodal involvement    0.22    0.10
 N0 0.42 (0.14–1.26)   0.87 (0.64–1.17)  
 N1mic 0.69 (0.18–2.62)   1.40 (0.91–2.17)  
 N1 (ref)       
HER2 status    0.82    0.33
 Negative 0.89 (0.49–1.62)   1.21 (0.55–2.92)  
 Borderline 0.63 (0.13–3.06)   1.26 (0.94–1.56)  
 Unknown (ref)       
Hormone receptor status       <0.001
 ER and PR both positive (ref)       
 Only ER or PR positive 0.80 (0.45–1.42)   0.58 (0.47–0.72)  
Histological grade    0.52    <0.001
 1–2 (well/moderately differentiated (ref)       
 3 (poorly or not differentiated) 1.18 (0.71–1.96)   0.68 (0.56–0.84)  
One year comorbidities    0.57    0.51
 0 (ref)       
 1 or more 0.86 (0.52–1.43)   0.92 (0.72–1.18)  
Surgery type    0.74    0.42
 Breast-conserving surgery (ref)       
 Mastectomy 0.94 (0.47–2.92)   0.93 (0.78–1.11)  
Chemotherapy    0.10    
 No (ref)       
 Yes 1.49 (0.92–2.39)     
Chemotherapy Tested       <0.001
 No Yes --    3.25 (2.53–4.16)  
No --      
 Yes Yes --    1.35 (0.96–1.90)  
No --      
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor